Assessing the limit of detection of Fourier-transform infrared spectroscopy and immunoassay strips for fentanyl in a real-world setting.
drug checking
fentanyl
harm reduction
opioids
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
31
08
2019
revised:
08
10
2019
accepted:
10
10
2019
pubmed:
21
11
2019
medline:
1
12
2020
entrez:
21
11
2019
Statut:
ppublish
Résumé
Drug checking is a harm reduction intervention increasingly used in the context of the opioid overdose epidemic. The aim of the study was to determine the limit of detection for fentanyl of two point-of-care drug checking technologies. Samples tested at point-of-care using Bruker Fourier transform infrared (FTIR) spectroscopy and BTNX fentanyl immunoassay strips were sent for confirmatory laboratory analysis using quantitative nuclear magnetic resonance (qNMR) spectroscopy. Concentrations by weight were determined and compared to results obtained with point-of-care methods. In total, 283 samples were sent for qNMR analysis; among these, 173 (61.1%) tested positive for fentanyl. As determined by qNMR, fentanyl concentration by weight ranged from 1% to 91%. Among these 173 samples, fentanyl was not detected in 30 (17.3%) samples by FTIR and in 4 (2.3%) samples by test strip. Samples containing fentanyl that went undetected by FTIR had concentrations ≤10%. The four samples containing fentanyl that went undetected by test strip had concentrations ≤5% (i.e. 1%, 3%, 4%, 5%). Fentanyl immunoassay strips were able to consistently detect the presence of fentanyl in samples at lower concentrations than FTIR spectroscopy. Given that FTIR spectroscopy is able to quantify content, mixture and concentrations on an array of compounds beyond just fentanyl but requires concentrations generally greater than 10%, these findings provide evidence for use of FTIR spectroscopy and immunoassay strips in combination to compensate for the limitations of each technology alone.
Substances chimiques
Analgesics, Opioid
0
Fentanyl
UF599785JZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-102Informations de copyright
© 2019 Australasian Professional Society on Alcohol and other Drugs.
Références
Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend 2018;190:242-5.
Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy 2019;63:122-8.
BC Centre on Substance Use. Drug checking as a Harm Reduction Intervention Evidence Review Report, 2017.
Measham FC. Drug safety testing, disposals and dealing in an English field: exploring the operational and behavioural outcomes of the UK's first onsite ‘drug checking’ service. Int J Drug Policy 2019;67:102-7.
Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J 2018;15:46.
Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J 2017;14:52.
Holzgrabe U, Deubner R, Schollmayer C, Waibel B. Quantitative NMR spectroscopy-applications in drug analysis. J Pharm Biomed Anal 2005;38:806-12.
Gerace E, Seganti F, Luciano C et al. On-site identification of psychoactive drugs by portable Raman spectroscopy during drug-checking service in electronic music events. Drug Alcohol Rev 2019;38:50-6.
Ellenhorn M, Barcelous D. Medical toxicology - diagnosis and treatment of human poisoning. New York: Elsevier Science Publishing Co., Inc., 1988:745.
Malz F, Jancke H. Validation of quantitative NMR. J Pharm Biomed Anal 2005;38:813-23.
Liu NQ, Choi YH, Verpoorte R, van der KF. Comparative quantitative analysis of artemisinin by chromatography and qNMR. Phytochem Anal 2010;21:451-6.
Sherman SG. FORECAST study summary report, 2018;
Furst RT. The re-engineering of heroin: an emerging heroin “cutting” trend in New York City. Addict Res 2000;8:357-79.
PubChem. Caffeine [Internet]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/2519 (accessed 29 July 2019).
PubChem. Fentanyl [Internet]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/3345 (accessed 29 July 2019).
National Institute of Standards and Technology, Water [Internet]. NIST Chemistry WebBook, SRD 69. Available at: https://webbook.nist.gov/cgi/cbook.cgi?ID=C7732185&Type=IR-SPEC&Index=1 (accessed 7 October 2019).
BTNX Inc. BTNX Fentanyl Strips Harm Reduction Brochure [Internet]. 2019. Available at: https://www.btnx.com/files/BTNX_Fentanyl_Strips_Harm_Reduction_Brochure.PDF (accessed 17 March 2019).
Drug Checking [Internet]. BCCSU. Available at: http://www.bccsu.ca/drug-checking/ (accessed 29 July 2019).